Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Alnylam & Medison Partner To Market RNAi Products In Israel

Published 01/22/2019, 07:58 AM
Updated 07/09/2023, 06:31 AM

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) entered into an exclusive agreement with Israel’s leading pharmaceuticals partner, Medison Pharma to commercialize its newly approved RNAi therapeutic Onpattro in Israel.

Alnylam makes use of a potentially radical RNAi technology. This technology is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to make the genes silent selectively through RNAi holds the potential to change the way diseases are treated.

Share price of Alnylam has declined 36.6% in the past year compared with the industry’s decline of 20.2%.

We remind investors that Onpattro was approved in the United States and Europe in August 2018 for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved RNAi therapeutic for this indication and not approved for use in Israel. The agreement also includes Alnylam’s investigational late-stage RNAi therapeutics — givosiran, being developed for the treatment of acute hepatic porphyria (AHP), and lumasiran, which is being developed for the treatment of Primary Hyperoxaluria Type 1 (PH1). Both givosiran and lumasiran have not been approved by any regulatory authority yet.

The agreement with Medison is in sync with the company’s strategy to globally expand so that it can make treatments of rare diseases accessible to patients across the globe. Medison has been successful at commercializing orphan products. The company has an infrastructure that is uniquely suited to support patients suffering from rare diseases in Israel. Per the agreement, Medison will have access to Alnylam’s Onpattro and other candidates that it can make available to physicians and patients in Israel.

Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate has allowed the company to enter into collaborations with leading pharmaceutical and life sciences companies like Ionis Pharmaceuticals, Novartis (NYSE:NVS) , Roche, Takeda, Merck (NYSE:MRK) The Medicines Company and Sanofi’s (NASDAQ:SNY) specialty care global business unit, Genzyme, among others.

Zacks Rank

Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>



Merck & Co., Inc. (MRK): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Sanofi (PA:SASY) (SNY): Free Stock Analysis Report

Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.